David T. Hagerty
Keine laufenden Positionen mehr
Profil
David T.
Hagerty worked as an Executive Director of Immunology at Bristol-Myers Squibb Pharmaceutical Research Institute from 1997 to 2006.
He then worked as Vice President of Immunology and Rheumatology at Biogen Idec, Inc. from 2006 to 2011.
From 2011 to 2013, he served as Chief Medical Officer and Senior Vice President at Ardea Biosciences, Inc. He was also the Executive Vice President of Clinical Development at Conatus Pharmaceuticals, Inc. from 2014 to 2019.
Hagerty received his undergraduate degree from the University of Notre Dame in 1977 and his doctorate from Saint Louis University School of Medicine in 1981.
Ehemalige bekannte Positionen von David T. Hagerty
| Unternehmen | Position | Ende |
|---|---|---|
| HISTOGEN INC. | Corporate Officer/Principal | 30.09.2019 |
Ardea Biosciences, Inc.
 Ardea Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Ardea Biosciences, Inc. is a biotechnology company which is focused on the development of small-molecule therapeutics for the treatment of serious diseases. The company was founded in January 1994 and is headquartered in Wilmington, DE. | Chief Tech/Sci/R&D Officer | 01.01.2013 |
Biogen Idec, Inc. (North Carolina)
 Biogen Idec, Inc. (North Carolina) Pharmaceuticals: MajorHealth Technology Part of Biogen, Inc., Biogen Idec, Inc. (North Carolina) is a pharmaceutical company based in Durham, NC. The private company develops pharmaceutical products. Michel Pericles Vounatsos has been the CEO of the company since 2016. | Corporate Officer/Principal | 01.01.2011 |
| Bristol-Myers Squibb Pharmaceutical Research Institute | Corporate Officer/Principal | 01.01.2006 |
Ausbildung von David T. Hagerty
| University of Notre Dame | Undergraduate Degree |
| Saint Louis University School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
Conatus Pharmaceuticals, Inc.
 Conatus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Conatus Pharmaceuticals, Inc. is a biotechnology company that focuses on the development and commercialization of novel medicines to treat chronic diseases. The firm engages in developing emricasan, an orally active pan-caspase inhibitor, for the treatment of patients with chronic liver disease and is designed to reduce the activities of human caspases. It also develops CTS-2090, an orally active selective caspase inhibitor, for diseases involving inflammasome pathways. The company was founded by Alfred P. Spada, Jennifer Giottonini Cayer, and Steven J. Mento on July 13, 2005 and is headquartered in San Diego, CA. | Health Technology |
Ardea Biosciences, Inc.
Ardea Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Ardea Biosciences, Inc. is a biotechnology company which is focused on the development of small-molecule therapeutics for the treatment of serious diseases. The company was founded in January 1994 and is headquartered in Wilmington, DE. | Health Technology |
Biogen Idec, Inc. (North Carolina)
Biogen Idec, Inc. (North Carolina) Pharmaceuticals: MajorHealth Technology Part of Biogen, Inc., Biogen Idec, Inc. (North Carolina) is a pharmaceutical company based in Durham, NC. The private company develops pharmaceutical products. Michel Pericles Vounatsos has been the CEO of the company since 2016. | Health Technology |
| Bristol-Myers Squibb Pharmaceutical Research Institute |
